Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
Osong Public Health and Research Perspectives
;
(6): 50-58, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-714235
ABSTRACT
OBJECTIVES:
To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).METHODS:
4 questionnaires were used to evaluate PROs before, during and after treatment Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).RESULTS:
Of the global sample of 55 patients included in this study; SOF + DCV (n = 10); SOF + DCV + RBV (n = 29); SOF + SMV (n = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment. No statistically significant differences in the PRO questionnaire values were observed between the distinct treatment regimens. The SOF and SMV patient groups presented higher mean PRO variations during and post-treatment, compared to the other groups SF-36 functional capacity (16.1); SF-36 mental health (21.4); CLDQ activity (1.8); CLDQ emotional function (1.2); FACIT-F physical well-being (8.0); Total FACIT-F (21.6).CONCLUSION:
Treatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Calidad de Vida
/
Ribavirina
/
Salud Mental
/
Enfermedad Crónica
/
Hepatitis C
/
Hepacivirus
/
Hepatitis C Crónica
/
Eficiencia
/
Simeprevir
Límite:
Humanos
Idioma:
Inglés
Revista:
Osong Public Health and Research Perspectives
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS